Transtech Pharma, Inc.

Novo Nordisk A/s

Vtv Therapeutics LLC

Daniel Peter Christen

Robert Carl Andrews

Dharma Rao Polisetti

Jesper F Lau

Adnan M M Mjalli

Anthony Murray

Kalpathy Chidambareswaran Santhosh

Lone Jeppesen

Michael Ankersen

Govindan Subramanian

Per Vedsø

Jeremy T Cooper

Jane Marie Lundbeck

Marit Kristiansen

Christopher Behme

Maria Carmen Valcarce-Lopez

Mustafa Guzel

Stephen Thomas Davis

Thomas Scott Yokum

Devi Reddy Gohimukkula

Muralidhar Bondlela

Ravindra Reddy Yarragunta

Jennifer L R Freeman

James C Quada, Jr

Bapu Reddy Gaddam

Guoxiang Huang

Robert Rothlein

Xiao-Chuan Guo

Devi Reddy Gohimmukkula

Sameer Tyagi

Tripura Yaramasu

Suparna Gupta

Maria Carmen Valcarce Lopez

Anitha Hari

Raju Bore Gowda

William Kenneth Banner

Per Vedsoe

Santhosh Kalpathy

Lone Jeppsen

James Quada

The present invention provides N-[1-(1-Cyclohexyl-3,5-dimethyl-1H-pyrazole-4-sulfonyl)-4-phenyl-piperidin-4-ylmethyl]-N-isobutyl-4-{[(piperidin-4-ylmethyl)-amino]-methyl}-benzenesulfonamide and pharmaceutically acceptable salts thereof. These compounds may be useful in the treatment of diseases such as Alzheimer's disease or renal failure. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating certain diseases.

Piperidine derivative and methods of use thereof

The present invention relates to substituted azoanthracene derivatives and intermediates for the preparation thereof. The substituted azoanthracene derivatives and associated intermediates may be useful for the preparation of pharmaceutical compositions for the treatment or prevention of diseases, disorders, and conditions wherein modulation of the human GLP-1 receptor is beneficial.

Substituted azoanthracene derivatives and intermediates for preparation thereof

The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.

Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof

This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

Heteroaryl-ureas and their use as glucokinase activators

The present invention relates to N-heteroaryl-benzamides, pharmaceutical compositions comprising the same, and methods of using the same. The N-heteroaryl-benzamides are useful in diseases or medical conditions mediated by glucokinase.

Benzamide glucokinase activators

This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.

N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes

This invention provides aryl and heteroaryl compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention may be antagonists, or partial antagonist of factor IX and/or factor XI and thus, may be useful for inhibiting the intrinsic pathway of blood coagulation. The compounds may be useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway.

Aryl and heteroaryl compounds, compositions, and methods of use

This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as antagonists, or more preferably, partial antagonist of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation. The compounds are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states.

Aryl and heteroaryl compounds and methods to modulate coagulation

Growing community of inventors

Jamestown, NC, United States of America

Daniel Peter Christen